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Abstract
The carbohydrate response element binding protein (ChREBP), a basic helix-loop-helix/leucine zipper transcription factor,
plays a critical role in the control of lipogenesis in the liver. To identify the direct targets of ChREBP on a genome-wide scale
and provide more insight into the mechanism by which ChREBP regulates glucose-responsive gene expression, we
performed chromatin immunoprecipitation-sequencing and gene expression analysis. We identified 1153 ChREBP binding
sites and 783 target genes using the chromatin from HepG2, a human hepatocellular carcinoma cell line. A motif search
revealed a refined consensus sequence (CABGTG-nnCnG-nGnSTG) to better represent critical elements of a functional
ChREBP binding sequence. Gene ontology analysis shows that ChREBP target genes are particularly associated with lipid,
fatty acid and steroid metabolism. In addition, other functional gene clusters related to transport, development and cell
motility are significantly enriched. Gene set enrichment analysis reveals that ChREBP target genes are highly correlated with
genes regulated by high glucose, providing a functional relevance to the genome-wide binding study. Furthermore, we
have demonstrated that ChREBP may function as a transcriptional repressor as well as an activator.
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Introduction
Glucose is a vital energy nutrient that provides carbon for
biosynthetic reactions and ATP for energy. Most organisms have
evolved diverse and sophisticated mechanisms for sensing glucose
and using it efficiently, including mechanisms for glucose-
dependent regulation of gene transcription. In mammals, the
molecular basis of glucose-regulated gene transcription was
revealed by the discovery and characterization of the carbohydrate
response element binding protein (ChREBP, MondoB and
WBSCR14), which is a glucose-responsive transcription factor
[1,2].
ChREBP is a basic helix-loop-helix leucine zipper transcrip-
tion factor, mediating glucose-regulated gene transcription.
Upon activation by glucose, ChREBP, whose expression is
most prominent in the liver, translocates from the cytosol into
the nucleus [3]. In the nucleus, ChREBP forms a heterodimer
with Max-like protein X (Mlx) to bind to the carbohydrate
response element (ChoRE) for transcriptional regulation of its
target genes [4,5,6]. ChREBP plays a critical role in hepatic
lipogenesis in response to high carbohydrate diet, converting
excess glucose to storage lipid. In ChREBP null mice, glycolytic
and lipogenic genes are not induced by high carbohydrate diet,
leading to reduced lipogenesis [7]. Loss of ChREBP in leptin-
null ob/ob mice alleviates obesity and corrects hepatic steatosis
[8,9].
To fully understand the molecular basis of glucose-regulated
gene transcription mediated by ChREBP, it is essential to identify
ChREBP target genes and their roles. It is known that ChREBP
regulates various enzymes involved in glycolysis and lipogenesis
such as pyruvate kinase, liver and RBC (PKLR), acetyl-CoA
carboxylase and fatty acid synthase (FASN) [10,11]. The full
transcriptional regulatory circuitry of ChREBP, however, is yet to
be understood. In the present study, we aimed to identify
ChREBP target genes and their roles on a genome-wide scale
using chromatin immunoprecipitation combined with massively
parallel sequencing technology (ChIP-seq) and gene expression
analysis [12,13].
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Results
Identification and characterization of ChREBP binding
sites using ChIP-seq analysis
To identify the complete repertoire of ChREBP target genes, we
treated HepG2 cells with 25 mM glucose for 8 h. This
experimental condition was determined by time course experi-
ments that measured the expression level changes of known
ChREBP target genes in response to 25 mM glucose (Figure S1).
Following initial testing of chromatin quality and ChIP efficiency
by ChIP-quantitative real-time PCR (ChIP-qPCR, data not
shown), ChIPed DNA and its control DNA were subjected to
deep sequencing. We obtained a total of 6,679,066 36-nucleotide
sequence tags from ChIPed DNA, and 5,992,478 sequence tags
from the control, which were uniquely mapped to the reference
genome, respectively.
ChREBP binding sites and their associated genes were identified
using PeakFinder [14] and CisGenome [15]. We identified a total of
1153 ChREBP binding sites with an average width of 398 bp
(Figure 1A). We searched for the peak proximal genes (,20 kb on
both sides) and identified total 783 nearest genes. Additional
information on the peak locations and their nearest genes is
provided in Table S1. We categorized ChREBP binding sites based
on their relative positions to the nearest genes using the University of
California at Santa Cruz genome annotation database for the
human genome (hg18, Build 36.1) [16]. According to our analysis,
16% of ChREBP binding sites were located within promoters and
13% of ChREBP binding sites were located within 2 kb upstream
region of the transcription start site (TSS) of annotated genes
(Figure 1B). A large proportion (38%) of ChREBP binding sites was
located within intergenic regions. Approximately 26% of peaks were
localized within introns; 15% of peaks were localized to the first or
second introns. The remaining sites were distributed mostly within
59 UTRs (14%) with very few located in 39 UTRs (1%) and exons
(5%). A similar genome-wide distribution pattern was found in
ChIP-Seq data for the transcription factors STAT1, CTCF and
NRSF [17]. A histogram of ChREBP binding sites located within
the genomic regions 20 kb downstream or upstream relative to
annotated TSSs shows clearly that most of the ChREBP binding
sites are enriched around the TSSs (Figure 1C).
Confirmation of identified ChREBP binding sites
ChREBP binding sites of representative ChREBP target genes,
PKLR [7], and thioredoxin interacting protein (TXNIP) [18] were
presented in Figure 2A and 2B. The vertical axis is the tag count of
overlapping mapped sequence reads at each nucleotide position
while peaks correspond to regions of DNA putatively bound by
ChREBP in HepG2 cells. To validate ChREBP binding sites
identified from ChIP-seq analysis, we performed ChIP-qPCR
using primers designed specifically for the ChREBP binding sites.
We first validated the enrichment of seven peak regions located in
six known ChREBP target genes: PKLR, TXNIP, basic helix-
loop-helix containing class E40 (bHLHE40) [19], FASN [7], Mid1
interacting protein 1 [20], and glyceraldehyde-3-phosphate
dehydrogenase (Figure 2C and S2). ChIP-qPCR analysis con-
firmed that the ChREBP binding sites are enriched in ChIPed
DNA with the greatest enrichment observed at the TXNIP
promoter (532-fold). To further validate novel ChREBP binding
sites, we randomly selected 37 binding regions of variable peak
intensity for ChIP-qPCR (Figure S2). All of the sites showed at
least 6-fold enrichment with ChREBP antibodies relative to
normal IgG, regardless of their relative locations to genes
(promoter, intron, exon, or intergenic region). In addition, the
enrichment of ChREBP binding sites in ChIPed DNA was
significantly enhanced in high glucose conditions, indicating
glucose affects the binding of ChREBP to DNA (Figure 3).
Unexpectedly, ChREBP binding sites associated with endothelin
converting enzyme 1 (ECE1), inhibin, beta E (INHBE) and
branched chain ketoacid dehydrogenase kinase (BCKDK) genes
showed more than 10-fold enrichment with ChREBP antibodies
relative to normal IgG even under low glucose conditions.
Identification of cis-regulatory motifs in the ChREBP
binding sites
To search for enriched motifs in the peaks from the ChIP-seq
dataset, we used the motif finding program W-ChIPMotifs [21]
and MEME [22]. Perfect E-boxes (CACGTG, PWM score = 1)
and the extended E-boxes (tCACGTGc, PWM score= 1,
CACGTGaaCA, PWM score= 0.956), were identified in the
ChREBP binding sites with strong enrichment (Figure 4A). Two
novel ChREBP binding motifs were identified using MEME
(Figure 4B). The first motif, termed as ChREBP binding motif 1
(ChBM1), is present in 901 peaks (78.9%, E= 3.9e2106, p,0.001).
ChBM1 consists of a perfect E-box and an imperfect E-box
separated by 5 nt (CABGTG-nnCnG-nGnSTG), resembling the
ChoRE consensus sequence (CAYGNG-n5-CNCRTG) [6].
Figure 4C represents the number of ChBM1 sites per peak and
approximately 54.6% of the ChREBP binding sites contain one or
two ChBM1 motifs. When ChREBP binding sites were scanned
with ChBM1 using a more stringent cutoff (p,0.0001), ChBM1-
derived sequence (CACGTG GCCGG CGCGTG) was found to
be present in 39.3% (453/1153, p,0.0001) of the 1153 peaks. The
second motif, termed as ChREBP binding motif 2 (ChBM2,
GGGGNRGGGSAGGGRGN) is present in 1152 peaks (99.9%,
E= 1.2e2281). Sequence-wise, ChBM2 significantly differs from
known ChREBP binding sites. Therefore, rather than being a
direct binding site for ChREBP, ChBM2 may represent binding
sites for ChREBP–associated proteins. TOMTOM analysis, which
compares a novel motif with known DNA-binding motifs in
TRANSFAC motif database [22], revealed that ChBM2 is
matched to Sp1-binding motif with the highest probability
[p=1.2e204, false-discovery rate (FDR) = 0.042].
To evaluate whether these two motifs, ChBM1 and ChBM2,
were bona fide binding sites of ChREBP, we performed electro-
phoretic mobility shift assay (EMSA). HEK293 cells were
transfected with expression vectors of ChREBP and heterodimer
partner Mlx and nuclear extracts were prepared. Nuclear extracts
were incubated with a radiolabeled oligonucleotide containing
ChBM1 or ChBM2 sequence (Figure 5). The results showed that
ChREBP/Mlx specifically binds to the ChBM1, but not to
ChBM2. The binding of ChREBP/Mlx to ChBM1 was
competitively inhibited by an excess of the corresponding
unlabeled wild type ChBM1 oligonucleotide (Figure 5A, lane 6
and 7), but not by adding the ChBM2 and nuclear factor kappa B
(NF-kB) (Figure 5A, lanes 8–11). The specificity of the ChREBP
binding to ChBM1 was further confirmed by performing super-
shift assay using antibodies that recognize ChREBP, as shown in
Figure 5A, lane 12. As for ChBM2, no significant band shift was
observed in comparison to that with vector nuclear lysates
(Figure 5B, lanes 2–5). In addition, adding ChREBP-specific
antibody had no effect on the migration of the band (Figure 5B,
lane 10). Collectively, these findings indicate that ChREBP/Mlx
binds to ChBM1, not to ChBM2, which reconciles with the
predictions from motif analysis.
Pathway analysis of ChREBP targets genes
To investigate the functional relationship of 783 ChREBP target
genes, the database for Annotation and Visualization, and the
ChREBP-Mediated Glucose Response Network Analyses
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22544
Figure 1. ChIP-seq analysis for ChREBP–DNA binding in human liver cells, HepG2. (A) Summary of peak analysis. (B) Location of ChREBP
binding peaks relative to known genes. The proximal and distal promoters are defined as 2 kb and 5 kb of 59-flanking DNA, respectively. The majority
of sites (38%) are located within an intergenic region; 16% are located in promoter regions. (C) Peak distance relative to TSS of the closest gene.
Negative distances indicate regions upstream of TSSs; positive distances indicate regions downstream of TSSs. Note that only the region around the
TSS is shown.
doi:10.1371/journal.pone.0022544.g001
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Integrated Discovery was used [23]. The pathways significantly
enriched [p-value,0.05] for ChREBP target genes were summa-
rized in Table 1. The pathway for lipid, fatty acid and steroid
metabolism is most significantly enriched by 48 novel ChREBP
target genes (p=1.03e24), supporting the central role of ChREBP
in lipid metabolism. Further investigation of ChREBP target genes
involved in this pathway identified the key enzymes of gluconeo-
genic pathway, such as phosphoenolpyruvate carboxykinase
Figure 2. Characterization of ChREBP binding sites at selected gene loci. (A, B) CisGenome Browser screenshots of peaks associated with
the PKLR and TXNIP genes. The y-axis shows the number of mapped tags. Annotations are from the UCSC Genome Browser. (C) Seven ChREBP
binding sites in six target genes showing peak height and fold enrichment. ChIP-qPCR was performed to confirm the identified ChREBP binding sites.
The fold enrichment is the fold increase for the signal from ChREBP ChIPed DNA relative to control IgG. Cyclophilin (Cyclo) and PKLR-4 kb were used
as negative controls (0.98- and 1.2-fold enrichment, respectively).
doi:10.1371/journal.pone.0022544.g002
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(PEPCK) and glucose-6-phosphatase catalytic subunit (G6Pase).
This result indicates that ChREBP may work as a dual regulator of
lipogenesis and gluconeogenesis, which have a reciprocal relation-
ship in response to glucose (Figure 6).
In addition, ChREBP target genes are associated with five
functional annotation clusters with enrichment scores above 2,
including protein dimerization, enzyme regulator activities,
embryonic development, carbohydrate metabolic process, and
lipid metabolism, suggesting broader roles of ChREBP in other
biologically important processes (Table S2).
Expression profiling of glucose-responsive genes and
their relationship with ChREBP target genes
To determine whether ChREBP binding to its target genes
change their expression levels, we performed gene expression
profiling analysis. Since the activity of ChREBP is regulated by
Figure 3. Effects of glucose on ChREBP binding. HepG2 cells were treated with low (2.7 mM) and high (25 mM) glucose for 8 h. Chromatin was
isolated and fragmented, and ChIP was performed with control IgG or anti-ChREBP antibody. Validated primers for each gene were used for
quantitative real-time PCR. The data presented as fold increase for the signal from anti-ChREBP relative to control IgG. The negative control, Cyclo,
showed no enrichment (data not shown). Values represent the mean6 S.D. of three independent samples. *p,0.005 vs. IgG, #p,0.0001 vs. 2.7 mM
glucose with anti-ChREBP.
doi:10.1371/journal.pone.0022544.g003
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glucose, we compared gene expression profiles of RNA isolated
from HepG2 cells cultured under either no- or high-glucose
conditions (in the same manner as cells used for ChIP-seq
analysis). The comparison of expression profiles between no- and
high-glucose conditions revealed that expression levels of 1822
genes were significantly changed by high glucose.
To compare the list of ChREBP target genes from the ChIP-seq
dataset with the gene expression profiling dataset, the expression
profiling dataset was rank-ordered by fold change such that the
most highly up-regulated genes under the high glucose condition
were at the top of the ranked list (Figure 7A). Interestingly, out of
109 ChREBP target genes are differentially expressed under the
high-glucose condition, 47% (51 genes) are up-regulated, and the
other 53% (58 genes) down-regulated. These observations indicate
that ChREBP functions as a transcriptional repressor as well as an
activator. Next, we ranked the list of genes by significance of
differential expression under the high glucose conditions and then
determined how the genes containing ChREBP binding sites were
distributed over the expression list using the modified Kolmo-
gorov–Smirnov (KS) test [24]. The analysis showed a highly
significant running enrichment score because the genes identified
by ChIP-seq were preferentially located toward the top of the
differentially expressed gene list (Figure 7B; p=1.5e211). Thus, the
distinct possibility exists that the ChIP-seq identified sites
correspond to functional sites of ChREBP action.
To further validate the relationship between ChREBP binding
and glucose-dependent gene regulation, the expression levels of
several genes including PKLR, TXNIP, sterol regulatory element
binding protein-1c (SREBP-1c), diacylglycerol O-acyltransferase
homolog 2 (DGAT2), pyruvate dehydrogenase kinase isozyme 2,
Figure 4. Enriched motifs in ChREBP binding sites in human liver DNA. The 1153 peak regions were analyzed for overrepresented motifs
using W-ChIPMotifs (A) and MEME (B). The three and two top-scoring motifs from each analysis are shown. (C) Number of ChBM1 motifs in a peak
identified by ChIP-seq (p,0.001).
doi:10.1371/journal.pone.0022544.g004
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INHBE, PEPCK, and solute carrier family 6 member 9 (SLC6A9)
were determined by reverse transcription/quantitative real-time
PCR (qRT-PCR). The binding of ChREBP to these genes was
already confirmed by ChIP-qPCR (Figure 3 and S2). Despite
ChREBP binding to all these genes, some genes are up-regulated
by glucose and others repressed (Figure 7C and 7D). Interestingly,
insulin responsive transcription factor SREBP-1c mRNA was
dramatically increased by high glucose (7-fold), suggesting that
ChREBP binds to SREBP-1c gene, transcriptionally activating its
expression in HepG2 cells. Moreover, PEPCK and G6Pase, two
rate-limiting enzymes of gluconeogenesis, were decreased in
response to high glucose (0.4-fold and 0.5-fold, respectively). To
determine the direct implication of ChREBP in glucose action on
expression of ChREBP target genes, we next silenced ChREBP in
HepG2 cells using short interfering RNAs (siRNAs). As shown in
Figure 7E, transfection of scrambled siRNAs did not affect the
expression of ChREBP, while ChREBP-specific siRNAs sup-
pressed ChREBP expression. Silencing of ChREBP in HepG2
cells reduced the expression of PKLR, DGAT2, stearoyl-CoA
desaturase 1 (SCD1), and TXNIP, but induced that of tribbles
homolog 3 (TRIB3) and SLC6A9. Our results show that the
majority of the ChREBP binding sites identified by the ChIP-seq
analysis are functionally important in mediating glucose-respon-
sive gene expression. In addition, our results indicate that
ChREBP may act as either an activator or a repressor within
the same biological context (e.g., as an activator of lipogenesis and
as a repressor of gluconeogenesis).
Discussion
The aim of the present study was to identify the direct targets of
ChREBP on a genome-wide scale and to understand the
Figure 5. Validation of ChREBP/Mlx binding to two enriched motifs, ChBM1 and ChBM2. Electrophoretic mobility shift assays were
performed with an oligonucleotide containing the ChBM1 (A) or ChBM2 (B) probe. All lanes contain the labeled probe, and lanes 2–12 contain 5 or
10 mg of HEK293 nuclear extract. Lanes 2 and 3 are HEK293 mock-transfected nuclear extract. The other lanes contain extract from HEK293 cells
transfected with the ChREBP and Mlx expression plasmids. For competition assays, a 10- or 50-molar excess of various unlabeled competitor DNAs
was added to the reaction mixture. Anti-ChREBP (Anti-ChBP, 0.6 mg) was added as indicated. The white arrow indicates the position of the ChREBP/
Mlx complex. The black arrow indicates the position of the antibody-supershifted complexes. The asterisks indicate the position of background bands
present in the control HEK293 cell nuclear extract.
doi:10.1371/journal.pone.0022544.g005
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underlying mechanism of glucose-responsive gene regulation by
ChREBP. ChIP-seq analysis revealed that ChREBP binds to 1153
sites across the genome, 45% of which are located in potential
gene regulatory regions including proximal/distal promoters, 59
UTRs, and the first/second introns of known genes. In addition,
the present study showed that the majority of the ChREBP
binding sites identified by the ChIP-seq analysis are functionally
important in mediating glucose-responsive gene expression with
ChREBP acting as either an activator or a repressor.
ChREBP binding sites and motifs
As mentioned above, 45% of ChREBP binding sites are closely
associated with TSSs, yet the rest are remotely associated with
TSSs. Previous genome-wide localization analysis of other
transcription factors such as Foxa2, ERa, Myc, and PPARc/
RXR also revealed that transcription factor binding sites can be
localized to regions other than the 59-proximal promoter regions,
such as far upstream sequences, introns, and 39 region of the gene
[25,26,27,28]. Whether these remotely associated sites may
function as enhancers or locus control regions (LCRs) is yet to
be discovered.
ChREBP forms a heterodimer with Mlx to bind to ChoRE. Ma
and colleagues [6] identified the consensus sequence of the ChoRE
as CAYGNG-n5-CNCRTG by analyzing functional ChoRE
sequences from seven different genes. According to the authors,
the heterotetramer formation between ChREBP/Mlx heterodi-
mers is essential to stabilize their binding to the tandem E box-like
sites (two imperfect CACGTG motifs) in ChoRE. In addition, the
stringent spacing between E boxes within ChoRE is critical for the
transcriptional response to glucose [29]. Consistent with these
previous observations, a refined sequence motif (ChBM1,
CABGTG-nnCnG-nGnSTG), similar to the ChoRE consensus
sequence, was predicted from ChREBP binding sites identified in
the present study. When ChREBP binding sites were scanned with
ChBM1 for further refinement of the consensus sequence using a
more stringent cut-off (p,0.0001), a new ChBM1-derived
sequence (CACGTG GCCGG CGCGTG) was acquired as a
consensus sequence, which is present in 39.3% (453/1153,
p,0.0001) of the 1153 peaks. The overall structure of this
ChBM1-derived sequence is precisely matched to that of ChoRE
consensus sequence, but with more details.
ChBM2 (GGGGNRGGGSAGGGRGN), one of the major
binding motifs, significantly differs from known ChREBP
binding sites and no direct ChREBP binding to ChBM2 was
observed in EMSA (Figure 5B). This may result from the
increased cross-links between ChREBP and other proteins by
relatively long fixation time, although we optimized the cross-
linking condition using two parameters to judge the best cross-
linking condition: average size of DNA after shearing and
analysis of the immunoprecipitation efficiency by qPCR (PLKR
was used as a positive control). It is also possible that ChREBP
and additional transcription factor may function together to
regulate gene expression. In fact, the regulatory effect of
ChREBP seems to depend on transcriptional modules made
up of ChREBP binding elements and other transcription factor
binding sites. Recently, a study showed that ChREBP can
cooperate with nuclear factor Y (NF-Y) to mediate induction of
TXNIP expression by glucose or adenosine-containing mole-
cules [30]. Our motif analysis revealed that ChBM2 is matched
to the Sp1 binding motif. Although no link has been reported
between ChREBP and Sp1, several reports have suggested that
Sp1, a ubiquitously expressed protein, may be involved in
glucose responsiveness. Members of the Sp1 family have been
proposed as being required for glucose-dependent induction of
the plasminogen activator inhibitor 1 [31], transforming growth
factor b [32] in vascular muscle cells and expression of neuronal
vesicular glutamate transporter isoform2 in pancreatic b-cells
[33]. Further mutagenesis and functional studies are necessary
to demonstrate clearly that ChBM2, a ChREBP-associated
motif, is a co-regulatory motif.
Correlation between ChREBP target genes and their
expression
Gene set enrichment analysis using the modified KS test
revealed a high degree of correlation between ChREBP binding
and ChREBP-dependent gene expression when HepG2 cells are
subjected to high glucose conditions (p= 1.5e211). Although
many ChREBP target genes were upregulated as expected given
the known role of ChREBP in activating glycolytic and
lipogenic genes, especially in the liver [1,5,7,34], some ChREBP
target genes were downregulated. The repressive effects of
ChREBP on glucose-mediated gene expression was further
Table 1. Analysis of the nearest gene dataset by the DAVID gene ontology program.
Panther Category (Biological Processes) Count p-Value FDR
BP00019:Lipid, fatty acid and steroid metabolism 53 1.03E-04 0.128
BP00141:Transport 73 2.59E-03 3.175
BP00287:Cell motility 26 3.00E-03 3.666
BP00063:Protein modification 60 2.61E-02 28.050
BP00027:Regulation of lipid, fatty acid and steroid metabolism 5 2.69E-02 28.788
BP00099:Phosphate transport 4 2.91E-02 30.689
BP00028:Lipid and fatty acid transport 11 3.04E-02 31.909
BP00285:Cell structure and motility 58 3.30E-02 34.070
BP00167:Synaptic transmission 19 3.73E-02 37.657
BP00067:Protein glycosylation 14 3.86E-02 38.671
BP00248:Mesoderm development 32 4.57E-02 44.112
BP00013:Amino acid metabolism 16 4.58E-02 44.183
BP00272:Phospholipid metabolism 12 4.59E-02 44.226
doi:10.1371/journal.pone.0022544.t001
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validated by qRT-PCR experiments showing decreased expres-
sion levels of genes such as PEPCK, G6Pase, INHBE, SLC6A9,
and TRIB3. Interestingly, PEPCK and G6Pase are rate-limiting
enzymes of gluconeogenesis, indicating that ChREBP may acts
as either an activator or a repressor within the same biological
context (e.g., as an activator of lipogenesis and as a repressor of
gluconeogenesis). This observation reconciles with the study of
Cairo and colleagues [2] that ChREBP may repress transcrip-
tion of target genes, depending on the context and/or
organization of E-box target sites in cell culture systems. In
addition, ChREBP was recently shown to repress ARNT/HIF-
1b in pancreatic b-cells [35], which is the first in vivo evidence
that ChREBP may play a repressive role in glucose responsive
transcription.
Functional clustering of ChREBP target genes
According to GO analysis, the functional group for lipid, fatty
acid and steroid metabolism was enriched by ChREBP target
genes in human liver cells. This observation is consistent with the
previous gene expression profiling using rodent hepatocytes and
liver. ChREBP null mice displayed lower mRNA levels of several
lipogenic enzymes, such as PKLR, FASN and SCD1, compared
with wild type mice [36]. In addition, Ma and colleagues [6]
showed that ChREBP activates the entire program of de novo
lipogenesis by gene profiling in the presence or absence of a
dominant-negative Mlx in rat hepatocytes cultured in high glucose
conditions. One of the identified ChREBP target genes, SREBP-
1c, is a key transcription factor in lipid metabolism [37]. We have
previously demonstrated that the expression of SREBP-1c gene is
Figure 6. Genes identified as ChREBP targets in De novo lipogenesis pathway. A schematic of the de novo lipogenesis pathway is shown.
Direct targets of ChREBP identified by ChIP-seq are indicated in boldface type. GKRP, glucokinase regulatory protein; G6Pase, glucose-6-phosphatase,
catalytic subunit; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PKLR, pyruvate kinase, liver and RBC; PCK1, phosphoenolpyruvate
carboxykinase1; LDH, lactate dehydrogenase A; DCT, dicarboxylate transporter; PDK2, pyruvate dehydrogenase kinase isozyme2; PDH, pyruvate
dehydrogenase; SDHAP3, succinate dehydrogenase complex, subunit A; FASN, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1; GPD1, glycerol-3-
phosphate dehydrogenase 1 (soluble); MOGAT2, monoacylglycerol O-acyltransferase 2; DGAT2, diacylglycerol O-acyltransferase homolog 2.
doi:10.1371/journal.pone.0022544.g006
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increased by glucose as well as insulin in mouse hepatocytes [38].
Interestingly, our ChIP-seq analysis and subsequent validation
studies revealed that ChREBP binds to the human SREBP-1c
gene. These results indicate that ChREBP is a mediator of glucose
action on SREBP-1c gene expression.
We also found that ChREBP target genes are functionally
related to cell motility. Although there is not known experimental
evidence regarding the role of ChREBP in cell migration, it is
shown that MondoA, a ChREBP paralog, regulates a number of
genes such as collagen type IV and fibulin 2, which are
components of ECM [39]. HepG2 cells are proliferative and
transformed cells whereas hepatocytes in the liver are largely
arrested in the G0 phase of the cell cycle. Therefore, enrichment of
ChREBP target genes in cell motility may be related to the
proliferative status of HepG2 cells. In this regard, Tong and
colleagues [40] have reported that the induction of ChREBP in
response to mitogenic signals is required for cell proliferation. Our
characterization of ChREBP binding profiles across the entire
human genome in HepG2 cells provides novel and important
insight into the regulation of ChREBP target gene network.
Although HepG2 cells have shown to express a wide range of liver-
specific functions as a reproducible human system, it is known that
some genes such as liver-specific transcription factors (hepatocyte
nuclear factors and C/EBPa) and drug metabolizing enzymes are
differently expressed in HepG2 cells compared to hepatocytes in
the liver [41]. Due to the limitation of the immortalized cell
system, further in vivo studies are required to fully elucidate
ChREBP regulated transcription in hepatocytes in the liver.
Materials and Methods
Cell culture
Human hepatocellular carcinoma HepG2 and human embry-
onic kidney (HEK) 293 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and
maintained in 25 mM glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
100 U/ml penicillin/streptomycin. For ChIP-seq and gene expres-
sion profiling, HepG2 cells (passage 8–10) were cultured in 2.7 mM
glucose DMEM with 10% FBS for 16 h and then cultured in 0, 2.7,
or 25 mM glucose medium for an additional 8 h.
To obtain nuclear extracts for gel shift assays, HEK293 cells
were transfected in 100 mm plates using Lipofectamine (Invitro-
gen) according to the manufacturer’s directions. Ten mg each of
expression plasmids of ChREBP and Mlx were cotransfected.
Nuclear extracts were prepared from cells 48 h post-transfection
using the ‘nuclear cell extract’ protocol in the Nuclear Extract kit
from ActiveMotif (Carlsbad. CA).
Chromatin immunoprecipitation-quantitative real-time
PCR (ChIP-qPCR)
ChIP assays were performed as previously described [42] with
minor modification. Briefly, HepG2 cells (16107 cells) previously
cultured in 2.7 mM or 25 mM glucose for 8 h were cross-linked
with 1% formaldehyde for 30 min at 37uC. The cross-linking
time was optimized using two parameters: average size of DNA
after shearing and analysis of the immunoprecipitation efficiency
by PCR. Cross-linking was stopped by the addition of glycine to a
final concentration of 0.125 M. The cells were washed three
times with ice-cold phosphate-buffered saline and kept on ice for
10 min in 25 mM HEPES (pH 7.8), 1.5 mM MgCl2, 10 mM
KCl, 0.1% Nonidet P-40, 1 mM dithiothreitol, 0.5 mM phenyl-
methylsulfonyl fluoride, and protease inhibitor cocktail (Roche,
Basel, Switzerland). Nuclei were collected and resuspended in
sonication buffer for 30 min on ice and sonicated on ice to an
average length of 200 bp using a tissue lyser set at 50%
amplitude. After sonication, the chromatin solution (500 mg)
was incubated with Dynabeads protein A (100.01D; Invitrogen,
Carlsbad, CA, USA) and 5 mg of rabbit anti-ChREBP (NB400-
135; Novus, St. Louis, MO, USA) or 5 mg of rabbit normal IgG
(sc-2027; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at
4uC overnight. Antibody-bound complexes were obtained and
DNA fragments extricated from these complexes were purified
using a QIAquick PCR Purification Kit (Qiagen, Shanghai,
China). The purified ChIPed DNA samples were analyzed by
qPCR using an Applied Biosystems Prism 7900HT sequence
detection system (Applied Biosystems, Carlsbad, CA, USA) and
SYBR-Green chemistry as described [43]. The qPCR oligonu-
cleotide pairs for the human promoters were validated by analysis
of template titration and dissociation curves and provided in
Table S3.
Sequencing and data analysis
For ChIP-seq library construction, ChIPed DNA was end-
repaired, ligated to adaptors, and amplified. Amplified fragments
of about 300 bp (with adaptors) were gel purified from 2%
agarose and used for sequencing on GAII (Illumina Inc., San
Diego, CA, USA) according to the manufacturer’s instructions.
Sequence reads were mapped to the human reference genome
using MAQ [44] and bowtie [45], and sequence reads that
mapped to multiple sites in the genome were removed. To
identify ChREBP binding regions, PeakFinder [14] and CisGen-
ome [15] were used for data analysis. In defining ChREBP
binding peaks, we used stringent settings, with the minimum
sequence reads set to 8 and the minimum read ratio comparing
ChREBP with input set to 5.
Annotation of genes and GO analysis
All ChREBP binding sites were assigned to nearest genes based
on the Homo sapiens NCBI Build 36.1 genome assembly (NCBI36/
hg18; March 2006). GO analysis for ChREBP target genes was
conducted using the NIH Database for Annotation, Visualization,
and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/)
[16]. The ChREBP target genes were classified into functionally
related gene groups using ‘PANTHER Biological Process’ term.
Figure 7. Correlation of ChREBP binding with gene expression. (A) Heat map view of a sample of ChREBP target genes exhibiting greater
than two-fold expression changes in the high glucose state. (B) KS plot. The ChIP-seq peaks were analyzed for their representation within an
expression array dataset from no vs. high glucose-treated HepG2 cells as described in the text. All genes in the microarray were ranked by posterior
probability of differential expression (PPDE) on the x-axis and the graph plots by the running enrichment score. (C, D) Experimental validation of
microarray results of 12 selected ChREBP target genes. HepG2 cells were incubated under 2.7 mM glucose conditions for 16 h. Cells were then either
kept in 0 or 25 mM glucose medium for 8 h and harvested for RNA preparation. The levels of target genes were determined by qRT-PCR. Expression
levels were normalized to expression of cyclophilin and mRNA levels in no glucose treated cells were set to 1. Values represent the mean of triplicate
samples 6 S.D. (E) Effects of ChREBP gene silencing on the expression of ChREBP target genes. HepG2 cells were transfected with 20 nmol of either
ChREBP siRNA or scrambled siRNA and incubated for 40 h in 2.7 mM DMEM. Then the cells were cultured in 25 mM glucose. After 8 h, total RNA was
extracted and analyzed for the expression of ChREBP target genes by qRT-PCR. Data represent the mean 6 S.D. of three independent transfections.
doi:10.1371/journal.pone.0022544.g007
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Motif analysis
We applied the motif-finding program W-ChIPMotifs [21] and
MEME [22] to ChREBP target peak regions to search for
statistically overrepresented consensus ChREBP binding sites in
the peak regions. Motifs were presented as position-dependent
letter-probability matrices.
Electrophoretic mobility shift assays (EMSA)
Probes for the EMSA were labeled with [c-32P]ATP using T4
polynucleotide kinase. Labeled double stranded oligonucleotides
were prepared by mixing a 5-fold molar excess of the
complementary single-stranded DNAs in 50 mM NaCl, heating
to 95uC for 5 min, and then cooling to room temperature. The
oligonucleotides used in these assays were as follows: ChBM1, 59-
TCG AGG CAC GTG GCC AGG GCC TGA TCG A-39;
ChBM2, 59-TCG ACC GGG GAA GGG CAG GGA GGG
GTC GA-39; NF-kB, 59-AGT TGA GGG GAC TTT CCC AGG
C-39.
The labeled probe (100,000 cpm) was combined with 5–
10 mg of nuclear extract from HEK293 cells in 75 mM of KCl,
7.5% (v/v) of glycerol, 20 mM of HEPES (pH 7.4), 0.1% (v/v)
of Nonidet P-40, and 2 mM of dithiothreitol. The nonspecific
competitors, 2 mg of poly dI-dC (Amersham Biosciences) and
20 pM of nonspecific antisense oligonucleotide were added in
each binding reaction. Following incubation with the labeled
probe for 30 min on ice, samples were subjected to electropho-
resis on a 4.5% nondenaturing polyacrylamide gel. For
reactions with antibodies, nuclear extract was preincubated
with antibody for 30 min on ice before addition of the probe.
For competition assays, a 10- or 50-molar excess of various
unlabeled competitor DNAs was added to the reaction mixture
prior to the addition of the probe. Results were visualized by
autoradiography.
Expression profiling (microarray) and data analysis
Total RNA from HepG2 cells was prepared using a Qiagen
RNeasy Kit. Total RNA from six biological replicates under 0 or
25 mM glucose conditions were then amplified into cRNA and
biotinylated by in vitro transcription using the Illumina total prep
RNA amplification kit (Ambion, Foster City, CA, USA) according
to the manufacturer’s instructions. Biotinylated cRNAs were then
hybridized to an Illumina HumanHT-12 BeadChip. Microarray
data were normalized and assessed for differential expression using
the LIMMA component (Linear Models for Microarray Data) of
the Bioconductor package [46] and the CyberT analysis program
[47]. The array data were submitted to Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi) under
accession number GSE22074.
Kolmogorov–Smirnov (KS) analysis
The ChIP-seq data were compared with expression micro-
array data using a KS plot, which is a modified method of
gene set enrichment analysis (GSEA) [24]. A KS plot can
determine whether our gene list from ChREBP ChIP-seq
tends to occur toward the top or bottom of the ranked gene
list of ChREBP expression microarray data. The genes in
gene expression microarray were rank-ordered by the
posterior probability of differential expression (PPDE) and
tested for matches between genes in the expression microarray
and the ChREBP ChIP-seq dataset. A KS plot was obtained
by calculating enrichment score, which was determined by
increasing a running sum if a match occurred, or by
decreasing it if no match was found.
Silencing of endogenous human ChREBP
HepG2 cells were transfected with siRNAs using RNAiMAX
according to the manufacturer’s directions (Invitrogen). A
scrambled siRNA (Stealth RNAi Negative Control Med GC)
was purchased from invitrogen and a siRNA for human ChREBP
(sense, 59-GGUAU AUCCA GUAUG UGAAU U-39; antisense,
5-UUCAC AUACU GGAUA UACCU U-39) was purchased
from Genolution (Seoul, Republic of Korea). Briefly, 16105 cells,
20 nM of RNAi medium, and 20 nmol of each ChREBP siRNA
or scrambled RNA incubated in serum reduced OPTI-MEM for
10 min and were plated in 12-well plates. The cells were cultured
in 2.7 mM glucose DMEM for 40 h and then cultured in 25 mM
glucose medium for an additional 8 h. The cells were lysed and
total RNA was extracted.
RNA measurement (Reverse transcription/quantitative
real-time PCR, qRT-PCR)
Total RNA was isolated from cultured cells using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). Two micrograms of
total RNA was treated with RNase-free DNase (Roche) and
reverse transcribed using SuperScript II (Invitrogen) and random
hexamers. Gene-specific primers were designed using Primer
Express Software (PerkinElmer Life Sciences, Waltham, MA,
USA) and validated by analysis of template titration and
dissociation curves. Primer sequences are provided in Table S3.
qRT-PCR was performed using an Applied Biosystems Prism
7900HT sequence detection system and SYBR-Green chemistry
as described [43]. Ten-microliter qRT-PCR reactions contained
25 ng of reverse-transcribed RNA, each primer (150 nM), and
5 ml of 26 SYBR Green PCR master mix (Applied Biosystems).
Results of qRT-PCR were evaluated by the comparative Ct
method (User Bulletin No. 2; PerkinElmer Life Sciences) using
cyclophilin as the invariant control gene. All samples were
analyzed in triplicate and expressed as the mean 6 S.D.
Supporting Information
Figure S1 Determination of the optimal condition for ChREBP
activation in HepG2 cells. HepG2 cells were cultured in 2.7 mM
glucose DMEM for 16 h and then cultured in high (25 mM)
glucose medium for an indicated time. Total RNA was extracted
and the PKLR and FAS gene expression was determined by qRT-
PCR. Expression levels were normalized to expression of
cyclophilin. Values represent the mean of triplicate samples 6
S.D.
(TIF)
Figure S2 Validation of ChIP-seq binding sites by single gene
ChIP-qPCR. ChIP-qPCR was performed on ChREBP-enriched
chromatin prepared from high glucose-treated HepG2 cells. All
randomly selected sites were validated by single gene ChIP-qPCR.
Positive control region (PKLR) and negative controls (PK-up, 4 kb
upstream region of PKLR and Cyclo, cyclophilin exon) were
included.
(TIF)
Table S1 The peak location and the nearest gene list. The
nearest genes to the ChREBP binding peaks are listed.
(PDF)
Table S2 Functional annotation clustering of the ChREBP
ChIP-seq dataset. To reduce redundancy, the newly developed
functional annotation clustering report groups and displays similar
annotations together to make the biology clearer and more focused
for reading when compared to a traditional chart report. For
annotation clustering, we used GOTERM_BP_ALL, GO-
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TERM_MF_ALL, PANTHER_BP_ALL, and PANTHER_M-
F_ALL.
(PDF)
Table S3 Primer sequences for the measurement of human
DNA or RNA using an ABI Prism 7900HT system. All primers
are listed in the 59 to 39 orientation.
(PDF)
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